Monday, March 19, 2007

Spaltudaq Raises $29M

Seattle-based Spaltudaq Corporation said late Friday that the biotechnology firm has raised $29M in a Series B funding. The funding came from ARCH Venture Partners, Canaan Partners, and HealthCare Ventures, which co-led the round. Additional investors included Amgen Ventures, MPM Capital, and Alexandria Equities. Spaltudaq is developing therapeutic human monoclonal antibodies which target infectious disease and cancer. More information »